(S)-(吗啉-3-甲基)氨基甲酸叔丁酯 | 1257850-88-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: (S)-(吗啉-3-甲基)氨基甲酸叔丁酯
• 中文别名: (S)-3-N-Boc-氨甲基吗啉
• 英文名称: (S)-tert-butyl (morpholin-3-ylmethyl)carbamate
• 英文别名: tert-butyl N-[[(3S)-morpholin-3-yl]methyl]carbamate
• CAS: 1257850-88-6
• 化学式: C₁₀H₂₀N₂O₃
• 分子量: 216.28
• InChiKey: OTGAMPLHQAGRIU-QMMMGPOBSA-N

物化性质

• 沸点：
  334.0±17.0 °C(Predicted)
• 密度：
  1.032±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  59.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  (S)-(吗啉-3-甲基)氨基甲酸叔丁酯 在 盐酸 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 (S)-ethyl 3-(aminomethyl)morpholine-4-carboxylate hydrochloride
  参考文献：
  名称：

  [EN] CARM1 INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE CARM1 ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2016044641A3

文献信息

• BENZIMIDAZOLE AND INDOLE COMPOUNDS AND USES THEREOF
  申请人：Incyte Corporation

  公开号：US20190315717A1

  公开（公告）日：2019-10-17

  Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

  揭示了式（I）的化合物，使用这些化合物抑制HPK1活性的方法以及包含这些化合物的药物组合物。这些化合物在治疗、预防或改善与HPK1活性相关的疾病或障碍，如癌症方面是有用的。
• Morpholine derivatives as antagonists of orexin receptors
  申请人：——

  公开号：US20040058921A1

  公开（公告）日：2004-03-25

  This invention relates to morpholine derivatives of formula (I) and their use as antagonists of orexin receptors.

  本发明涉及公式（I）的吗啡啶衍生物及其作为促进睡眠荷尔蒙受体拮抗剂的用途。
• CARM1 INHIBITORS AND USES THEREOF
  申请人：EPIZYME, INC.

  公开号：US20160039834A1

  公开（公告）日：2016-02-11

  Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R 1 , R 1a , R 2a , R 2b , R 2c , R 2d , are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula (II) wherein L 2 , R 13 , G 8 , G 10 , G 11 , and G 12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

  本文提供了式（I）的化合物及其药学上可接受的盐，以及它们的制药组合物；其中，X、R1、R1a、R2a、R2b、R2c、R2d的定义如本文所述，Ring HET是式（II）的6元单环杂芳基环系统，其中L2、R13、G8、G10、G11和G12的定义如本文所述。本发明的化合物对抑制CARM1活性有用。还描述了使用这些化合物治疗CARM1介导的疾病的方法。
• CARM1 inhibitors and uses thereof
  申请人：Epizyme, Inc.

  公开号：US10118931B2

  公开（公告）日：2018-11-06

  Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

  本文提供的是式 (I) 化合物： 及其药学上可接受的盐类和药物组合物，其中 X、R1、R1a、R2a、R2b、R2c、R2d 如本文所定义，环 HET 是式中的 6 元单环杂芳基环系统： 其中 L2、R13、G8、G10、G11 和 G12 如本文所定义。本发明的化合物可用于抑制 CARM1 活性。还描述了使用这些化合物治疗 CARM1 介导的疾病的方法。
• Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model
  作者：Christoph W. Zapf、Jonathan D. Bloom、Jamie L. McBean、Russell G. Dushin、Jennifer M. Golas、Hao Liu、Judy Lucas、Frank Boschelli、Erik Vogan、Jeremy I. Levin

  DOI：10.1016/j.bmcl.2011.04.102

  日期：2011.6

  A novel series of macrocyclic ortho-aminobenzamide Hsp90 inhibitors is reported. In continuation of our research, heterocycle-containing tethers were explored with the intent to further improve potency and minimize hERG liabilities. This effort culminated in the discovery of compound 10, which efficiently suppressed proliferation of HCT116 and U87 cells. This compound showed prolonged Hsp90-inhibitory activity at least 24 h post-administration consistent with elevated and prolonged exposure in the tumor. When studied in a xenograft model, the compound demonstrated significant suppression of tumor growth. (C) 2011 Elsevier Ltd. All rights reserved.